Intervention not reported
Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension
The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).
1 finding from 1 review
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Intervention not reported
HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).
1 finding from 1 review
Intervention not reported
HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma
1 finding from 1 review
Intervention not reported
Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Spasticity at up to 6 hours after treatment (measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity) · adults with traumatic brain injury with spasticity in their arms and legs
1 finding from 1 review
Sensory functions and pain · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neuromusculoskeletal and movement‐related functions at 12 weeks (measured by ankle dorsiflexion) · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
1 finding from 1 review
General tasks and demands · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mobility · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐care · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Spasticity at up to 6 hours after treatment (measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Adverse events · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Sensory functions and pain · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found